ArticleScientific reports2026
Synthesis, in-vitro and in-silico bioactivity and computational studies of pyrene and p-methoxycinnamaldehyde linked 4-hydroxycoumarins.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
4-Hydroxycoumarin is a well-known pharmacophore of significant relevance in medicinal and pharmaceutical chemistry. The pursuit of multifunctional therapeutic agents continues to inspire the exploration of coumarin-based scaffolds. The derivatives of 4-hydroxycoumarin have been intriguing to researchers for drug design, synthesis, and the investigation of their therapeutic potential particularly against microbial infections and cancer. This study reports the design, synthesis, structural characterization and comprehensive in-vitro and in-silico evaluation of two novel 4-hydroxycoumarin derivatives: 3,3'-(pyren-1-ylmethylene) bis(4-hydroxy-2 H-chromen-2-one) (PBHC) and (E)-3,3'-(3-(4-methoxyphenyl) prop-2-ene-1,1-diyl) bis(4-hydroxy-2 H-chromen-2-one) (MPBHC). The antibacterial and anti-cancer activity of these derivatives are evaluated. The cytotoxicity was assessed on HEK-293 normal cells to evaluate selectivity. PBHC and MPBHC were synthesized and structurally confirmed through, FT-IR, NMR, HRMS and UV-Vis spectroscopic techniques. Quantum chemical investigations employing density functional theory (DFT, B3LYP/6-311 + G(d, p)) and time-dependent DFT (TD-DFT) accurately reproduced the electronic absorption spectra and provided insights into electronic transitions Molecular electrostatic potential (MESP) mapping, Frontier molecular orbital (FMO) analysis and topological investigations consisting of ELF, LOL, ALIF, NCI-RGD, and QTAIM analyses were conducted to identify the reactive centers and characterize the non-covalent interaction networks. As per the biological evaluation studies it was observed that PBHC displayed significant antibacterial activity against Staphylococcus aureus and exhibited selective cytotoxicity toward HepG2 hepatocellular carcinoma cells (IC₅₀ = 46.69 ± 0.021 µM, the cytotoxicity of PBHC towards HEK-293 normal cells shows an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.